Published: 17.07.2026, Redaktion boerse-global.de
Researchers have recently decoded the cellular mechanism linking Epstein-Barr Virus (EBV) to Multiple Sclerosis (MS). A study published in the journal Science Translational Medicine on July 15, 2026, reveals that EBV activates specific CD4+ T-cells, which subsequently attack the myelin sheaths of neurons. Notably, the activity of these T-cells is found to be twice as high in MS patients compared to healthy individuals.
Understanding the Immune Response
The immune response primarily targets lytic proteins of the virus, suggesting that an EBV infection can occur years before MS symptoms emerge. This delayed onset is crucial for understanding how chronic inflammation and immune activation lead to MS.
Therapeutic Approaches: Old Drugs, New Insights
The research also investigated the effects of existing treatments. An anti-CD20 therapy was found to decrease CD4+ T-cell responses by a factor of 2.5, while reducing or completely eliminating EBV shedding in saliva. Among emerging therapies, Frexalimab has gained attention as it specifically blocks CD4+ T-cell activity, interrupting the inflammatory cascade.
Unpacking these mechanisms paves the way for EBV-specific antiviral therapies and vaccines, which could complement or replace traditional immunosuppression methods.
EBV: Ubiquitous Yet Rarely Detrimental
Interestingly, despite the global prevalence of the Epstein-Barr virus—approximately 90% of people carry it—only a small fraction, around 2.9 million worldwide or 1 million in the USA, develop MS. A landmark study from 2022 indicated that EBV infection increases the risk of MS by 32 times.
Adding to this conversation, a recent study published in Cell Genomics on the same date reveals that EBV significantly influences human gene regulation. Viral proteins bind to specific regions of the genome, controlling gene expression. This interaction could have implications beyond MS, extending to other autoimmune diseases and certain cancers.
The Next Challenge: Prevention
The new findings underscore how an EBV infection escalates the risk of developing MS. As the scientific community focuses on targeted therapies such as Anti-CD20, Frexalimab, and potential vaccines, the need for preventive measures remains paramount. Identifying the exact proteins that trigger immune attacks is essential for designing future vaccines aimed at preventing MS.
In conclusion, the ongoing research elucidates the critical role EBV plays in T-cell activation in MS, steering towards innovative therapeutic avenues. With continued exploration, the dream of preventing MS may become a reality.
Disclaimer: This article is not an investment advisory, and no recommendations for buying or selling are included. Data on a company’s market movements is subject to change without notice. Stock trading can result in significant financial losses. Our contributions are processed, supported, and reviewed through AI technologies.
